Cytlimic Inc.
Records under this name other than patents Cytlimic Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Cytlimic Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,537,626 | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,304,997 | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,526,388 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,590,179 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,875,900 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,842,848 | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,491,204 | Composition comprising poly I:C and LAG-3-IGG fusion protein Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,291,718 | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,759,518 | Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,448,413 | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell Formerly held In force · USPTO record | In force | USPTO record |